John Oyler Sells 2,789 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNE) CEO John Oyler sold 2,789 shares of BeiGene stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $159.58, for a total transaction of $445,068.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

John Oyler also recently made the following trade(s):

• On Wednesday, April 10th, John Oyler sold 26,716 shares of BeiGene stock. The shares were sold at an average price of $148.89, for a total value of $3,977,745.24.

BeiGene Stock Performance

BeiGene stock opened at $145.58 on Friday. The stock has a 50-day simple moving average of $156.67 and a 200 day simple moving average of $160.09. The stock has a market capitalization of $13.95 billion, a price-to-earnings ratio of -19.23 and a beta of 0.60. The company has a quick ratio of 1.84, a current ratio of 2.08 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $225.23.

BeiGene (NASDAQ:BGNE) last released its earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.07) by $0.66. The company had revenue of $751.70 million during the quarter, compared to the consensus estimate of $670.09 million. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The firm’s quarterly revenue was up 67.9% on a year-over-year basis. During the same quarter in the previous year, the company posted ($3.34) earnings per share. On average, research analysts anticipate that BeiGene, Ltd. will post -8.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on BGNE. Bank of America lowered their target price on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a research note on Monday, April 8th. JPMorgan Chase & Co. upped their price objective on shares of BeiGene from $184.00 to $186.00 and gave the stock an “overweight” rating in a report on Tuesday, March 19th. Sanford C. Bernstein lowered their price objective on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a report on Wednesday, March 27th. Finally, TD Cowen lifted their price objective on BeiGene from $236.00 to $254.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $251.93.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new position in shares of BeiGene in the 1st quarter valued at $50,000. Toronto Dominion Bank boosted its holdings in shares of BeiGene by 166.4% in the third quarter. Toronto Dominion Bank now owns 333 shares of the company’s stock valued at $60,000 after buying an additional 208 shares during the period. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of BeiGene during the fourth quarter worth $98,000. PNC Financial Services Group Inc. lifted its position in BeiGene by 123.9% in the 3rd quarter. PNC Financial Services Group Inc. now owns 732 shares of the company’s stock valued at $132,000 after acquiring an additional 405 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in BeiGene in the 4th quarter worth $183,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.